Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-08-08
2006-08-08
Woltach, Joseph (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07087586
ABSTRACT:
The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.
REFERENCES:
patent: 5851984 (1998-12-01), Matthews et al.
patent: 5866332 (1999-02-01), Cocks et al.
patent: 5994320 (1999-11-01), Low et al.
Adunyah, S.E. et al., “Regulation of c-jun mRNA expression by hydroxyurea in human K562 cells during erythroid differentiation”, Biochim. Biphys. Acta, vol. 1263, pp. 123-132, 1995.
Bates, P.J. et al., “Antiproliferative activity of G-rich oligonucleotides correlates with protein binding” J. Biol. Chem., vol. 274, No. 37, pp. 26369-26377, 1999.
Beran, M. et al., “Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice”, Hematol. Pathol., vol. 8, No. 4, pp. 135-154, 1994.
Bianchi, N. et al., “Induction of erythroid differentiation of human K562 cells by cisplatin analogs”, Biochem. Pharmacol., vol. 60, No. 1, pp. 31-40, 2000.
Bianchi, N. et al., “The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells”, Br. J. Haematol., vol. 104, No. 2, pp. 258-265, 1999.
Bianchi Scarra, G.L., et al., “Terminal erythroid differentiation in the K-562 cell line by 1-beta-D-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease”, Cancer Res, vol. 46, pp. 6327-6332, 1986.
Brem, H. et al., “Interstitial Chemotherapy with drug polymer implants for the treatment of recurrent gliomas,” J. Neurosurg., vol. 74, pp. 441-446, 1991.
Cartron, J.P., “Defining the Rh Blood Group antigens, Biochemistry and molecular genetics”, Blood Rev., vol. 8, Issue 4, pp. 199-212, 1994.
Cortesi, R. et al., “Human leukemic K562 cells treated with cytosine arabinoside: enhancement of erythroid differentiation by retinoic acid and retinol”, Eur J Haematol, vol. 61, No. 1, pp. 295-301, 1998.
Decker, T. et al., “Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells”, Blood, vol. 95, No. 3, pp. 999-1006, 2000.
Daniels, G. and Green, C., “Expression of red cell surface antigens during erythropoiesis”, Vox Sang, vol. 78 (suppl. 2), pp. 149-153, 2000.
Drexler, H.G., “Leukemia cell lines: in vitro models for the study of chronic myeloid leukemia,” Leuk. Res., vol. 18, issue 12, pp. 919-927, 1994.
DSMZ Catalogue of Human and Animal Cell Lines, 6thed., Braunschweig, Germany: DSMZ 1997.
Gambari, R. et al., “Human leukemic K562 cells: suppression of hemoglobin accumulation by a monoclonal antibody to human transferring receptor”, Biochem. Biophys. Acta, vol. 886, No. 1, pp. 203-213, 1986.
Gambari, R. et al., “Efficient cell proliferation and predominant accumulation of epsilon-globin mRNA in human leukemic K562 cells which produce mostly Hb Gower 1”, Experientia, vol. 41, pp. 673-675, 1985.
Gruel, Y. et al., “Determination of platelet antigens and glycoproteins in the human fetus”, Blood, vol. 68, No. 2, pp. 488-492, 1986.
Iyamu, E.W. et al., “Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells”, Biochem. Biophys. Res. Commun., vol. 247, No. 3, pp. 759-764, 1998.
Morassutti, C. et al., “Effect of oligomer length and base substitutions on the cytotoxic activity and specific nuclear protein recognition of GTn oligonucleotides in the human leukemic CCRF-CEM cell line”, Nucleosides & Nucleotides, vol. 18, No. 6-7, pp. 1711-1716, 1999.
Osti, F. et al., “Human leukemia K562 cells: induction to erythroid differentiation by guanine, guanosine and guanine nucleotides”, Haematologica, vol. 82, pp. 395-401, 1997.
Rutherford, T.R. et al., “K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin”, Nature, vol. 280, pp. 164-165, 1979.
Scaggiante, B. et al., “Human cancer cell lines growth inhibition by GTn oligodeoxyribonucleotides recognizing single-stranded DNA-binding proteins”, Eur. J. Biochem, vol. 252, No. 2, pp. 207-215, 1998.
Schwenke, K. et a., “Induction of differentiation in erythroleukemic K562 cells by gamma-irradiation”, Leuk. Res., vol. 19, No. 12, pp. 955-961, 1995.
Tidd, D.M., et al., “Oligodeoxynucleotide 5mers containing a 5′-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells”, Nucleic Acids Res., vol. 28, No. 11, pp. 2242-2250, 2000.
Vlassov, V.V. et al. “Transport of oligonucleotides across natural and model membranes” Biochem. Biophys. Acta, vol. 1197, No. 2, pp. 95-108, 1994.
Wagner, R.W., “Gene inhibition using antisense oligodeoxynucleotides”, Nature, vol. 372, No. 6504, pp. 333-335, 1994.
Wheater, et al., “Functional Histology, a text and color atlas”, 2d ed. Churchill Livingstone UK, Blood, pp. 57-58, 1987.
Wright, S.D. et al., “CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein”, Science, vol. 249, Issue 4975, pp. 1431-1433, 1990.
Filion Mario C.
Phillips Nigel C.
Bioniche Life Sciences Inc.
Kilpatrick & Stockton LLP
Woltach Joseph
LandOfFree
Oligonucleotide compositions and their use to induce... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide compositions and their use to induce..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide compositions and their use to induce... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695190